Market LIVE
Published markets; coverage varies by country
Product profile · United States

VIRAMUNE XR

 ·  Patent Litigation & Settlement History ↓

IngredientNEVIRAPINE
Application typeNDA
Application201152
Product001
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
Strength400MG
Approval date2011-03-25
Marketing statusDiscontinued
Status event—
ApplicantBOEHRINGER INGELHEIM
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2014-04-03
Status event—

Final ANDA candidate 203411/001 on 2014-04-03. Source-level RLD/TE screen; earliest Final and exact Product source reference require independent review.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
84607042029-03-12U U-1409———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
205921 / 001APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——MYLAN LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207064 / 001APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——CIPLA LIMITEDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
203411 / 001FINAL_APPROVAL · FINAL_APPROVED2014-04-03—SANDOZ INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
205258 / 001FINAL_APPROVAL · FINAL_APPROVED2014-04-03—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
205651 / 001FINAL_APPROVAL · FINAL_APPROVED2014-10-27—MYLAN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
204621 / 001FINAL_APPROVAL · FINAL_APPROVED2015-07-10—ALVOGEN INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
206448 / 001FINAL_APPROVAL · FINAL_APPROVED2015-10-15—CIPLA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207698 / 001FINAL_APPROVAL · FINAL_APPROVED2017-02-28—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207467 / 002FINAL_APPROVAL · FINAL_APPROVED2017-07-31—TECHNOLOGY ORGANIZED LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
206879 / 001FINAL_APPROVAL · FINAL_APPROVED2017-10-06—MACLEODS PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 8 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
203411 / 001SANDOZ INCFINAL_APPROVAL · FINAL_APPROVED2014-04-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
205258 / 001APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2014-04-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
205651 / 001MYLAN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2014-10-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
204621 / 001ALVOGEN INCFINAL_APPROVAL · FINAL_APPROVED2015-07-10 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
206448 / 001CIPLA LTDFINAL_APPROVAL · FINAL_APPROVED2015-10-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
207698 / 001AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2017-02-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
207467 / 002TECHNOLOGY ORGANIZED LLCFINAL_APPROVAL · FINAL_APPROVED2017-07-31 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
206879 / 001MACLEODS PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2017-10-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.